David A. Siegel Xilio Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $47 Billion
- Q3 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Xilio Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 29,689 shares of XLO stock, worth $20,782. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29,689Holding current value
$20,782% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding XLO
# of Institutions
35Shares Held
11MCall Options Held
0Put Options Held
0-
Bain Capital Life Sciences Investors, LLC Boston, MA4.57MShares$3.2 Million1.25% of portfolio
-
River Vest Venture Management LLC St. Louis, MO1.44MShares$1.01 Million16.6% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.26MShares$878,9840.0% of portfolio
-
Morgan Stanley New York, NY962KShares$673,3410.0% of portfolio
-
Aju Ib Investment Co., Ltd. Seoul, M5668KShares$467,4190.49% of portfolio
About Xilio Therapeutics, Inc.
- Ticker XLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 27,471,600
- Market Cap $19.2M
- Description
- Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine prog...